SynthesisThe pharmacogenomics journal2009
APOE gene polymorphisms and response to statin therapy.
Synthesis in The pharmacogenomics journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- APOE genotype and the effect of statins on lipid outcomes: A meta-analysis.British journal of clinical pharmacology · 2026Pooled it
- Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.European heart journal · 2013Trial
- APOE Genotype and Statin Response: Evidence From the UK Biobank and All of Us Program.Clinical and translational science · 2025Article
- Article
- Genetic Determinants of Response to Statins in Cardiovascular Diseases.Current cardiology reviews · 2024Review
- Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab.Molecular genetics and genomics : MGG · 2022Article
- Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke.Frontiers in cardiovascular medicine · 2022Article
- The SNPs rs429358 and rs7412 of APOE gene are association with cerebral infarction but not SNPs rs2306283 and rs4149056 of SLCO1B1 gene in southern Chinese Hakka population.Lipids in health and disease · 2020Article
- Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia.Lipids in health and disease · 2019Article
- Strength training attenuates post-infarct cardiac dysfunction and remodeling.The journal of physiological sciences : JPS · 2019Article
- Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China.Journal of clinical laboratory analysis · 2018Article
- Ten-year progress of coronary artery lesions prior to Behçet disease diagnosis: A case report and care-compliant article.Medicine · 2017Article
- Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.International journal of molecular sciences · 2017Review
- ESR1 polymorphisms and statin therapy: a sex-specific approach.The pharmacogenomics journal · 2016Article
- Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases.Frontiers in pharmacology · 2016Article
- Genetics and personalized medicine--a role in statin therapy?Current atherosclerosis reports · 2014Review
- Pharmacogenomics and cardiovascular disease.Current cardiology reports · 2013Review
- Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.Pharmacogenomics · 2013Article
- Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.Lipids in health and disease · 2011Article
- Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises.Current atherosclerosis reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Published studies investigating the role of APOE gene on lipid response (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides) to statin treatment have reported inconsistent results. A meta-analysis was conducted to estimate the lipid response to statin treatment among APOE genetic variants (e2 carriers, e3e3 homozygotes and e4 carriers). Twenty-four studies were included in the meta-analyses. The pooled mean reduction (Delta mu) in TC from baseline was significant for all variants (e2 carriers: Delta mu=-27.7% (-32.5 to -22.8%), e3e3: Delta mu=-25.3% (-28.0 to -22.6%) and e4 carriers: Delta mu=-25.1% (-29.3 to -21.0%)). Significant changes in LDL-C, HDL-C and triglyceride levels were also noted for all genotypes, although these changes did not differ significantly among genotypic groups. There was significant heterogeneity among the studies. Given these non-significant effects of APOE genotypes on lipid responses, there is little reason to consider the use of APOE genetic testing for guiding treatment with statins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.